FDA: Page 42


  • Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    Boston Scientific, Sterigenics start tracking ethylene oxide emissions under new EPA rules

    Beginning this month, 29 medical device sterilization facilities must comply with EPA's Toxics Release Inventory reporting requirements for EtO, which has been determined to cause cancer in humans and damage DNA.

    By Jan. 21, 2022
  • A staff member from McSwain Union Elementary School District in Merced, California participates in the district's voluntary COVID-19 testing pilot.
    Image attribution tooltip
    Permission granted by Roy Mendiola
    Image attribution tooltip

    Diagnostics makers ride omicron surge in COVID-19 test demand. But for how long in 2022?

    The highly transmissible variant caused the Biden administration to announce plans to buy 1 billion rapid tests to provide free to Americans. However, when testing will ramp back down remains an open question.  

    By Jan. 20, 2022
  • Boston Scientific's Farapulse pulsed field ablation device. Explore the Trendlineâž”
    Image attribution tooltip
    Permission granted by Boston Scientific
    Image attribution tooltip
    Trendline

    New medical devices are reshaping the medtech industry

    From pulsed field ablation devices to glucose sensors and surgical robotics, new medical technologies are transforming patient care and how people manage their health.

    By MedTech Dive staff
  • The sign identifying the FDA headquarters in front of its building in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA misses MDUFA V deadline after months of contentious talks

    The agency has failed to send the final MDUFA V user fee agreement to Congress by the Jan. 15 deadline, suggesting there may be unresolved disagreements with industry over elements of the program.

    By Jan. 19, 2022
  • Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    CDRH pledges greater focus on women's health data

    The center's strategic plan creates a framework for addressing FDA's priorities in the area of women's health, including representation in biomedical research.

    By Jan. 19, 2022
  • Communication network concept. GUI (Graphical User Interface).
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Digital therapeutics face barriers to growth as Pear takes early steps toward sales targets

    Among the challenges facing DTx are lack of support for rapid updates, limitations of current reimbursement policies, cybersecurity risks as well as a "pressing need" for new regulatory frameworks, according to researchers.

    By Jan. 19, 2022
  • Professional photo of Kevin Sayer
    Image attribution tooltip
    Permission granted by Dexcom
    Image attribution tooltip
    Q&A

    Dexcom CEO on G7's global launch, COVID-19 slowing new patient adds, international growth

    Kevin Sayer spoke to MedTech Dive about the upcoming launch of the G7 CGM system, further expanding Dexcom ONE and feeling pandemic pressure in the fourth quarter.

    By Jan. 18, 2022
  • A single opened padlock glows red among rows of closed blue padlocks.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Cybersecurity leads ECRI's list of top medtech hazards for 2022

    Cyber incidents can compromise patient care and attacks against hospitals have become more prevalent in recent years. However, ECRI said the worst consequences are preventable.

    By Jan. 18, 2022
  • President Joe Biden announces his winter COVID-19 plan as concerns grow over a new variant.
    Image attribution tooltip

    WhiteHouse.gov

    Image attribution tooltip

    Biden administration to buy 500M more rapid COVID-19 tests to give to Americans

    The announcement by President Joe Biden now brings the administration's total purchase to 1 billion test kits. Abbott Laboratories, iHealth and Roche have so far been awarded contracts for a combined 380 million tests.

    By Jan. 14, 2022
  • The sign identifying the FDA headquarters in front of its building in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA advises physicians to consider alternatives to Endologix AFX2 endovascular grafts

    The agency said providers need to be aware that "the majority of available data" link earlier AFX endovascular graft versions to more health risks compared to similar treatments. Cook Medical and Medtronic could benefit.

    By Jan. 14, 2022
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Neurological devices, diagnostics dominate latest FDA breakthrough designations

    The agency has granted breakthrough designations to several devices for neurological conditions, including an autism test and treatment as well as diagnosis of Parkinson's disease.

    By Jan. 13, 2022
  • Notified body shortage remains pressing as industry prepares for staggered IVDR rollout

    Three months have passed since the European Commission warned about a "grave shortage of notified body capacity," but the situation is largely unchanged.

    By Jan. 13, 2022
  • Philips ups recall provisions by $250M, impacted devices to more than 5M

    The Dutch medtech said the recall and supply chain issues are the primary reasons for missing fourth-quarter sales expectations by about $400 million. Philips' shares were down more than 15% early Wednesday.

    By Jan. 12, 2022
  • Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    Biden health officials defend COVID-19 testing policies amid diagnostics shortage

    Acting FDA Commissioner Janet Woodcock and others were under fire from senators during a Tuesday hearing for not doing enough to increase the availability of tests.   

    By Jan. 12, 2022
  • The sign identifying the FDA headquarters in front of its building in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA seeks feedback on draft device shortage guidance

    A new document poses a series of questions for industry on the overall design and operation of the policy, and is intended to help manufacturers provide timely information about supply disruptions during public health emergencies.

    By Jan. 12, 2022
  • iRhythm Zio XT
    Image attribution tooltip
    Permission granted by iRhythm Technologies
    Image attribution tooltip

    iRhythm stock jumps nearly 28% after Novitas doubles Medicare rates for cardiac monitoring

    The new rates give the cardiac monitor maker a boost following a challenging 2021. After a Monday spike, iRhythm's stock price was also up by nearly 9% when the market closed Tuesday.

    By Jan. 11, 2022
  • Image attribution tooltip
    Nic Antaya via Getty Images
    Image attribution tooltip

    Insurers will be required to cover 8 at-home COVID-19 tests per month

    After proposing the plan in December, the Biden administration on Monday detailed its plan to have insurers cover rapid tests. Health insurance lobby AHIP warned of potential "hiccups in early days" of implementation.

    By Jan. 11, 2022
  • Image attribution tooltip
    Medtronic
    Image attribution tooltip

    Medtronic CEO: Company on track to hit guidance, omicron impact 'uncertain'

    Geoff Martha, who spoke on the opening day of J.P. Morgan's healthcare conference, said the medtech is being impacted by both the delta and omicron variants, including ongoing pressure from hospital staffing shortages.

    By Jan. 10, 2022
  • FDA warning letter cites product safety issues in Medtronic diabetes group

    The agency was critical of how long Medtronic took to recall certain MiniMed insulin pumps, despite over 57,000 medical device reports being filed with the FDA over more than three years.

    By Jan. 5, 2022
  • Image attribution tooltip
    Quinn Rooney via Getty Images
    Image attribution tooltip

    Roche, Siemens at-home tests get EUAs as US faces COVID-19 testing shortage

    FDA granted emergency use authorizations to the over-the-counter diagnostics under a new accelerated review program. However, the companies may need months to scale up production.

    By Jan. 4, 2022
  • iRhythm Zio XT
    Image attribution tooltip
    Permission granted by iRhythm Technologies
    Image attribution tooltip

    iRhythm's Medicare pricing saga defined its 2021

    The cardiac monitor maker had a series of setbacks following Novitas Solutions' Medicare rate cut, including a stock free fall and a new CEO resigning after 4 months. Here's our coverage of iRhythm in 2021. 

    Dec. 30, 2021
  • User growth, product delays and a Super Bowl ad: Diabetes tech heads into 2022 after another eventful year

    Diabetes tech companies are heading into 2022 with momentum as insulin pump and CGM use climbs and with key product launches on the horizon. Here are MedTech Dive's top sector stories in 2021.

    Dec. 28, 2021
  • Philips: Compounds in recalled devices 'not typically' associated with long-term health risks

    Despite further testing, the company did not change its guidance for physicians or patients, which was given due to the recall of millions of sleep apnea and ventilator machines.

    By Updated Dec. 23, 2021
  • Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA seeks feedback on 180-day notice period for termination of COVID-19 EUAs

    The agency's plan is intended to avoid supply disruptions while moving back toward the regulatory requirements of routine operations.

    By Dec. 23, 2021
  • Image attribution tooltip
    Brian Tucker
    Image attribution tooltip

    CDRH warns review timelines will remain extended in 2022 as pandemic pressures continue

    The FDA's Center for Devices and Radiological Health expects "a gradual transition back toward normal review timelines" next year as COVID-19 has delayed traditional work.

    By Dec. 22, 2021
  • Image attribution tooltip
    Drew Angerer via Getty Images
    Image attribution tooltip

    Biden stresses need for additional testing supply, plans to distribute 500M free rapid COVID-19 tests

    "We have to do more. We have to do better — and we will," President Joe Biden acknowledged on Tuesday, as a surge in omicron cases has put added stress on America's already strained test supply.

    By Updated Dec. 22, 2021